Upfront docetaxel in M1
Systematic review and meta-analysis
Trial name
Overall
STAMPEDE (SOC+ZA +/- DOC)
STAMPEDE (SOC +/- DOC)
GETUG15
CHAARTED
HR = 0.77 (95% CI: 0.68-0.87);
P
<0.000
.5
1
2
Heterogeneity:
2
=4.80, df=3,
P
=0.187,
I
2
= 37.5%
Favors SOC+DOC
Favors SOC
•
Results based on 2,993 men /1,254 deaths
10% absolute improvement in survival (from 40% to 50%) at 4 years
Vale CL et al. Lancet Oncol 2016;17:243-56
SAEU.CAB.16.07.0040j
